Eckert & Ziegler is awarded the Contract for Radiodiagnostics in Gdansk
Eckert & Ziegler Strahlen- und Medizintechnik AG / Contract
21.06.2010 14:01
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
Berlin, 21 June 2010. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a specialist for special preparations for the diagnosis and treatment of cancer has been awarded the tendered contract for the regular supplies of radiodiagnostics to the Polish Medical University of Gdansk via its subsidiary Eckert & Ziegler f-con Deutschland GmbH. The contract valued at approx. Euro 1.3 million relates to the diagnostic substance fluor deoxyglucose (FDG), which is used for the reliable and quick diagnosis of the smallest tumours via positron emission computer-assisted tomography (PET). Due to its short half-life time FDG must be locally manufactured daily using cyclotrons, enabling fresh supplies to the clinics. The Managing Director, Axel Schmidt, declared: 'Our tender was convincing because of our track record in Poland where we have been supplying Polish specialists in nuclear medicine with reliable deliveries of FDG for many years. Our intention, in addition to our market leadership in Germany and Poland, is to continue extending our manufacturing network and consolidating it with further production locations.'
Eckert & Ziegler already has several radiopharmaceutical manufacturing locations in Germany and also markets, in addition to Fluor 18-based radiodiagnostics for nuclear medical imaging (PET), the licensed product Yttriga, a precursor of many radio therapeutics. In addition Eckert & Ziegler supplies nuclear medical facilities with synthesis technology and Gallium-68-radionuclide generators.
About Eckert & Ziegler
Eckert & Ziegler Strahlen- und Medizintechnik AG is a global isotope technology company and holding company for a number of specialized subsidiary companies in the field of processing of radioisotopes and of development, production, and marketing of isotope technology components, medical devices, and similar products. The quoted group generated a turnover of EUR 101 million in 2009 and is one of the largest suppliers of radioactive components for radiation therapy and nuclear medicine, employing 520 employees worldwide. Please visit our website at www.ezag.com for more information on Eckert & Ziegler.
Eckert & Ziegler AG, Karolin Riehle, Investor Relations, Robert-Rössle-Str. 10, 13125 Berlin, Tel.: +49 (0) 30 / 94 10 84-138, Fax -112, E-Mail: karolin.riehle@ezag.de, www.ezag.de
21.06.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG Robert-Rössle-Str.10
13125 Berlin
Deutschland
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700, DE000A0L1L69
WKN: 565970, A0L1L6
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart; Freiverkehr in Berlin, München, Düsseldorf, Hamburg
End of News DGAP News-Service